联合二代测序与流式细胞术分析一例抗PD-L1部分缓解者的时间变化:膀胱癌中PD-L1活性与耐药机制的探索
本文报告一例接受抗PD-L1治疗的转移性尿路上皮癌患者,在5年间对多份肿瘤标本进行RNA测序、全外显子组测序(WES)和流式细胞术的首次联合分析。抗PD-L1初始敏感性与肿瘤转为基底分子亚型及肿瘤突变负荷升高相关;随着耐药出现,调节性T细胞和表达CTLA-4、TIM-3、LAG-3等替代免疫检查点的CD8+ T细胞比例增加,提示替代免疫检查点上调可能是抗PD-L1耐药的一种形式。
要点
- 抗PD-L1初始敏感性与肿瘤转为基底分子亚型及肿瘤突变负荷升高相关。
- 耐药出现时调节性T细胞及表达CTLA-4、TIM-3、LAG-3的CD8+ T细胞比例增加。
- 替代免疫检查点上调可能是尿路上皮癌抗PD-L1耐药的一种形式。
核心结论
- 替代免疫检查点上调可能是尿路上皮癌抗PD-L1耐药的一种形式。
- 这些数据支持尿路上皮癌联合免疫检查点阻断的概念,该概念正在前瞻性临床试验中评估。
研究设计与样本
- 对一例接受抗PD-L1治疗的转移性尿路上皮癌患者,在5年期间对多份肿瘤标本进行RNA测序、全外显子组测序(WES)和流式细胞术的首次联合分析。
主要发现
- 抗PD-L1初始敏感性与肿瘤转为基底分子亚型及肿瘤突变负荷升高相关。
- 随着肿瘤对αPD-L1更加耐药,调节性T细胞和表达CTLA-4、TIM-3、LAG-3等替代免疫检查点的CD8+ T细胞比例增加。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Anti-PD-L1/PD-1 immunotherapy has improved survival for certain patients with metastatic urothelial carcinoma. However, the mechanisms of resistance to these agents have not been fully elucidated. We report the first combined analysis using RNA sequencing, whole-exome sequencing (WES), and flow cytometry of multiple tumor specimens over a 5-yr period for a patient undergoing anti-PD-L1 therapy. Initial sensitivity to anti-PD-L1 immunotherapy was associated with conversion to a basal molecular subtype and a rising tumor mutational burden. We found that as the tumor became more resistant to anti-PD-L1, the proportion of regulatory T cells and CD8+ T cells expressing alternative immune checkpoints including CTLA-4, TIM-3, and LAG-3 increased. This suggests that alternative immune checkpoint upregulation may be one form of anti-PD-L1 resistance in urothelial carcinoma. These data support the concept of combined immune checkpoint blockade for urothelial carcinoma, a concept that is being evaluated in prospective clinical trials. PATIENT SUMMARY: In this study we characterized how a patient with metastatic urothelial cancer became resistant to anti-PD-L1 immunotherapy. By tracking changes in protein and gene expression over time, we found that as urothelial carcinoma becomes resistant to PD-L1 blockade, additional immune checkpoints may be upregulated. These data support the concept of combined checkpoint blockade for urothelial carcinoma.
引用
- Kates M, Nirschl TR, Baras AS, et al. Combined Next-generation Sequencing and Flow Cytometry Analysis for an Anti-PD-L1 Partial Responder over Time: An Exploration of Mechanisms of PD-L1 Activity and Resistance in Bladder Cancer. Eur Urol Oncol. 2019. PMID: 31411999. doi:10.1016/j.euo.2019.01.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。